Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05183802 Approved for marketing - Obesity Clinical Trials

An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

Start date: n/a
Phase:
Study type: Expanded Access

An open-label, single-arm, multicenter, Expanded Access Protocol [EAP] designed to provide treatment access to setmelanotide (3 mg, administered subcutaneously [SC], once daily) for eligible patients with BBS who have no alternative treatment options. All patients will continue to receive setmelanotide at the discretion of the Treating Physician and while they are deriving clinical benefit.

NCT ID: NCT04530994 Approved for marketing - Alagille Syndrome Clinical Trials

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

Start date: n/a
Phase:
Study type: Expanded Access

An open-label, single-arm, multi-centre program providing treatment access to ALGS patients with cholestatic pruritus in the US. Access can be requested through Clinigen Healthcare Ltd via email MirumALGS@clinigengroup.com or telephone +1-877-768-4303.

NCT ID: NCT03780127 Approved for marketing - Dravet Syndrome Clinical Trials

ZX008 Expanded Access Protocol

Start date: n/a
Phase:
Study type: Expanded Access

The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 clinical trials.

NCT ID: NCT01983722 Approved for marketing - Dravet Syndrome Clinical Trials

Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome

Start date: n/a
Phase:
Study type: Expanded Access

Expanded access to Stiripentol for patients with Dravet Syndrome.

NCT ID: NCT01825395 Approved for marketing - Clinical trials for Lambert Eaton Myasthenic Syndrome

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

3 4-DAP
Start date: n/a
Phase:
Study type: Expanded Access

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

NCT ID: NCT01220531 Approved for marketing - DiGeorge Syndrome Clinical Trials

Thymus Transplantation Safety-Efficacy

Start date: n/a
Phase:
Study type: Expanded Access

Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Without successful treatment, patients with cDGA must remain in reverse isolation to prevent infection and subsequent death. Cultured thymus tissue with and without immunosuppression (drugs given before and after implantation) has resulted in the development of good T cell function in subjects with complete DiGeorge anomaly. This expanded access study continues cultured thymus tissue safety and efficacy research for the treatment of complete DiGeorge anomaly. Eligible participants receive cultured thymus tissue. Immune function testing is continued for one year post-implantation.

NCT ID: NCT00872950 Approved for marketing - Clinical trials for Congenital Myasthenic Syndrome

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

LEMS
Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).